Humalog Kwikpen U-200 (Insulin Lispro) — Medicare Part D spending
Eli Lilly & Co. · Rank #205 by total Part D spend · CMS data year 2023
Medicare Part D spent $224,440,404 on Humalog Kwikpen U-200 (Insulin Lispro) in 2023, the #205 drug by total Part D spending out of 3,598 drugs. That worked out to about $73.76 per dosage unit, $1,559 per claim and $5,527 per beneficiary, across 143,978 claims for 40,611 beneficiaries. Average spending per dosage unit rose +0.8% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Humalog Kwikpen U-200 (Insulin Lispro) spending at a glance (2023)
| Metric | Humalog Kwikpen U-200 (Insulin Lispro) |
|---|---|
| Total Part D spending (2023) | $224,440,404 |
| Total spending (2022) | $195,020,098 |
| Year-over-year change in total spending | +15.1% |
| Average spending per dosage unit (2023) | $73.76 |
| Change in spend per dosage unit (YoY) | +0.8% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +1.0% |
| Average spending per claim (2023) | $1,559 |
| Average spending per beneficiary (2023) | $5,527 |
| Total claims (2023) | 143,978 |
| Beneficiaries (2023) | 40,611 |
| Total dosage units (2023) | 3,042,936 |
| Manufacturer(s) | Eli Lilly & Co. |
| National rank by total spend (of 3,598 drugs) | #205 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $195,020,098 | $224,440,404 | +15.1% |
| Avg spend per dosage unit | $73.20 | $73.76 | +0.8% |
| Avg spend per claim | $1,505 | $1,559 | — |
| Avg spend per beneficiary | $5,394 | $5,527 | — |
| Total claims | 129,581 | 143,978 | — |
| Beneficiaries | 36,156 | 40,611 | — |
How Humalog Kwikpen U-200 compares with nearby drugs
Drugs with total Part D spending closest to Humalog Kwikpen U-200 (Insulin Lispro):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Humalog Kwikpen U-200 (Insulin Lispro) (this drug, #205) | $224,440,404 | $73.76 | +0.8% |
| Icosapent Ethyl (#203) | $228,873,224 | $2.04 | -4.3% |
| Korlym (Mifepristone) (#204) | $228,814,734 | $632.17 | +9.0% |
| Soliris (Eculizumab) (#206) | $223,473,529 | $228.56 | +0.9% |
| Gammaked (Immune Globul G/Gly/IgA Avg 46) (#207) | $220,007,929 | $18.74 | +10.1% |
| Trazodone HCl (#208) | $216,388,379 | $0.21 | +0.6% |
Frequently asked questions
How much does Medicare Part D spend on Humalog Kwikpen U-200?
Medicare Part D spent $224,440,404 on Humalog Kwikpen U-200 (Insulin Lispro) in 2023 (the latest CMS data year), across 143,978 claims for 40,611 beneficiaries. That ranks #205 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Humalog Kwikpen U-200?
In 2023, the weighted average Medicare Part D spending per dosage unit for Humalog Kwikpen U-200 (Insulin Lispro) was $73.76. Compared with 2022 it rose +0.8%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Humalog Kwikpen U-200?
CMS attributes Humalog Kwikpen U-200 (Insulin Lispro) to Eli Lilly & Co. in the 2023 Part D spending file. Average spending per claim was $1,559 and per beneficiary $5,527.
Is the Humalog Kwikpen U-200 figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20